References
- Advance Care Planning Australia. (2021). Advance care planning explained Austin Health. Retrieved 18 March from
https://www.advancecareplanning.org.au/understand-advance-care-planning/advance-care-planning-explained - Aradi, S. D., & Hauser, R. A. (2020). Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurotherapeutics, 17(4), 1339–1365.
https://doi.org/10.1007/s13311-020-00889-4 - Barrachina-Fernández, M., Maitín, A. M., Sánchez-Ávila, C., & Romero, J. P. (2021). Wearable Technology to Detect Motor Fluctuations in Parkinson's Disease Patients: Current State and Challenges. Sensors (Basel), 21(12).
https://doi.org/10.3390/s21124188 - Barthel, C., Mallia, E., Debu, B., Bloem, B. R., & Ferraye, M. U. (2016). The Practicalities of Assessing Freezing of Gait. Journal of Parkinson's Disease, 6, 667–674.
https://doi.org/10.3233/JPD-160927 - Beitz, J. M. (2014). Parkinson's disease: a review. Front Biosci (Schol Ed), 6(1), 65–74.
https://doi.org/10.2741/s415 - Bhasin, S. K., & Bharadwaj, I. U. (2021). Perceptions and meanings of living with Parkinson's disease: an account of caregivers lived experiences. International journal of qualitative studies on health and well-being, 16(1), 1967263–1967263.
https://doi.org/10.1080/17482631.2021.1967263 - Bhat, S., Acharya, U. R., Hagiwara, Y., Dadmehr, N., & Adeli, H. (2018). Parkinson's disease: Cause factors, measurable indicators, and early diagnosis. Comput Biol Med, 102, 234–241.
https://doi.org/10.1016/j.compbiomed.2018.09.008 - Borghammer, P., & Van Den Berge, N. (2019). Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. J Parkinsons Dis, 9(s2), S281–s295.
https://doi.org/10.3233/jpd-191721 - Carbone, F., Djamshidian, A., Seppi, K., & Poewe, W. (2019). Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs, 33(9), 905–918.
https://doi.org/10.1007/s40263-019-00661-z - Eichel, H. V., Heine, J., Wegner, F., Rogozinski, S., Stiel, S., Groh, A., Krey, L., Höglinger, G. U., & Klietz, M. (2022). Neuropsychiatric Symptoms in Parkinson's Disease Patients Are Associated with Reduced Health-Related Quality of Life and Increased Caregiver Burden. Brain Sci, 12(1).
https://doi.org/10.3390/brainsci12010089 - Foltynie, T., Magee, C., James, C., Webster, G. J. M., Lees, A. J., & Limousin, P. (2013). Impact of Duodopa on Quality of Life in Advanced Parkinson's Disease: A UK Case Series. Parkinsons Dis, 2013, 362908–362905.
https://doi.org/10.1155/2013/362908 - Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., Dubois, B., Holloway, R., Jankovic, J., Kulisevsky, J., Lang, A. E., Lees, A., Leurgans, S., LeWitt, P. A., Nyenhuis, D., Olanow, C. W., Rascol, O., Schrag, A., Teresi, J. A., van Hilten, J. J., & LaPelle, N. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov. Disord, 23(15), 2129–2170.
https://doi.org/10.1002/mds.22340 - Greenland, J. C., Williams-Gray, C. H., & Barker, R. A. (2019). The clinical heterogeneity of Parkinson's disease and its therapeutic implications. Eur J Neurosci, 49(3), 328–338.
https://doi.org/10.1111/ejn.14094 - Grissinger, M. (2018). Delayed Administration and Contraindicated Drugs Place Hospitalized Parkinson's Disease Patients at Risk. P & T : a peer-reviewed journal for formulary management, 43(1), 10–39.
https://pubmed.ncbi.nlm.nih.gov/29290668 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737245/ - Grover, S., Somaiya, M., Kumar, S., & Avasthi, A. (2015). Psychiatric aspects of Parkinson's disease. J Neurosci Rural Pract, 6(1), 65–76.
https://doi.org/10.4103/0976-3147.143197 - Hartmann, C. J., Fliegen, S., Groiss, S. J., Wojtecki, L., & Schnitzler, A. (2019). An update on best practice of deep brain stimulation in Parkinson's disease. Ther Adv Neurol Disord, 12, 1756286419838096–1756286419838096.
https://doi.org/10.1177/1756286419838096 - Hayes, M. W., Fung, V. S., Kimber, T. E., & O’Sullivan, J. D. (2010). Current concepts in the management of Parkinson disease. The Medical Journal of Australia, 192(3), 144–149.
- Hung, A. Y., & Schwarzschild, M. A. (2014). Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics, 11(1), 34–46.
https://doi.org/10.1007/s13311-013-0239-9 - Jose, A., Bhargavan, A., Appireddy, R., Raghunath, P., Rajan, R., & Iype, T. (2021). Neuropsychiatric Symptoms and Caregiver's Burden in Parkinson's Disease Patients in a Tertiary Care Teaching Hospital in South India: A Cross-Sectional Study. Neurology India, 69(6), 1706–1710.
https://doi.org/10.4103/0028-3886.333437 - Kaiserova, M., Grambalova, Z., Kurcova, S., Otruba, P., Prikrylova Vranova, H., Mensikova, K., & Kanovsky, P. (2021). Premotor Parkinson's disease: Overview of clinical symptoms and current diagnostic methods. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 165(2), 103–112.
https://doi.org/10.5507/bp.2021.002 - Kujawska, M., & Jodynis-Liebert, J. (2018). What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut? Int J Mol Sci, 19(11).
https://doi.org/10.3390/ijms19113573 - Lee, T. K., & Yankee, E. L. (2021). A review on Parkinson's disease treatment. Neuroimmunology and Neuroinflammation, 8, 222.
https://doi.org/10.20517/2347-8659.2020.58 - Lees, A. (2017). An essay on the shaking palsy. Brain, 140(3), 843–848.
https://doi.org/10.1093/brain/awx035 - Lo Buono, V., Palmeri, R., De Salvo, S., Berenati, M., Greco, A., Ciurleo, R., Sorbera, C., Cimino, V., Corallo, F., Bramanti, P., Marino, S., Di Lorenzo, G., & Bonanno, L. (2021). Anxiety, depression, and quality of life in Parkinson's disease: the implications of multidisciplinary treatment. Neural Regen Res, 16(3), 587–590.
https://doi.org/10.4103/1673-5374.293151 - Martini, A., Weis, L., Schifano, R., Pistonesi, F., Fiorenzato, E., Antonini, A., & Biundo, R. (2020). Differences in cognitive profiles between Lewy body and Parkinson's disease dementia. Journal of Neural Transmission, 127(3), 323–330.
https://doi.org/10.1007/s00702-019-02129-2 - Mohamad, K. A., Wahdan, S. A., & Elnaga, R. N. (2021). Overview on Parkinson's disease: pathophysiology, and experimental models. Archives of Pharmaceutical Sciences Ain Shams University, 5(2), 212–224.
https://doi.org/10.21608/aps.2021.92639.1068 - Nakmode, D. D., Day, C. M., Song, Y., & Garg, S. (2023). The Management of Parkinson's Disease: An Overview of the Current Advancements in Drug Delivery Systems. Pharmaceutics, 15(5).
https://doi.org/10.3390/pharmaceutics15051503 - Nolden, L. F., Tartavoulle, T., & Porche, D. J. (2014). Parkinson's Disease: Assessment, Diagnosis, and Management. Journal for nurse practitioners, 10(7), 500–506.
https://doi.org/10.1016/j.nurpra.2014.04.019 - Postuma, R. B., Berg, D., Adler, C. H., Bloem, B. R., Chan, P., Deuschl, G., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., Lang, A. E., Liepelt-Scarfone, I., Litvan, I., Marek, K., Oertel, W., Olanow, C. W., Poewe, W., & Stern, M. (2016). The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol, 15(6), 546–548.
https://doi.org/10.1016/S1474-4422(16)00116-2 - Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J. A., & Kraneveld, A. D. (2017). Exploring Braak's Hypothesis of Parkinson's Disease [Review]. Frontiers in neurology, 8.
https://doi.org/10.3389/fneur.2017.00037 - Rispoli, V., Simioni, V., Capone, J. G., Golfrè Andreasi, N., Preda, F., Sette, E., Tugnoli, V., & Sensi, M. (2017). Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation. Acta Neurol Scand, 136(6), 660–667.
https://doi.org/10.1111/ane.12783 - Samson, E., & Noseworthy, M. D. (2022). A review of diagnostic imaging approaches to assessing Parkinson's disease. Brain Disorders, 6, 100037.
https://doi.org/https://doi.org/10.1016/j.dscb.2022.100037 - Simioni, V., Sette, E., Capone, J. G., Preda, F., Granieri, E., Sensi, M., & Tugnoli, V. (2016). 50. Peripheral neuropathy associated with Duodopa infusion: neurophysiological retrospective study. Clinical neurophysiology, 127(12), e335–e335.
https://doi.org/10.1016/j.clinph.2016.10.062 - Spliethoff-Kamminga, N. G. A., Zwinderman, A. H., Springer, M. P., & Roos, R. A. C. (2003). A disease-specific psychosocial questionnaire for Parkinson's disease caregivers. J Neurol, 250(10), 1162–1168.
https://doi.org/10.1007/s00415-003-0165-6 - Taki, S., Maekita, T., Sakata, M., Fukatsu, K., Maeda, Y., Iguchi, M., Ito, H., & Kitano, M. (2019). Migration of a percutaneous endoscopic gastrojejunostomy tube into the colon with small intestinal telescoping. Clin Endosc, 52(6), 616–619.
https://doi.org/10.5946/ce.2019.016 - Tsui, D. S.-Y. (2014). The Tomorrow: Advanced Treatments in Parkinson's Disease Does Not Necessarily Equate to Treatments in Advanced Parkinson's Disease Australasian Journal of Neuroscience, 24(2), 34–37.
- Tysnes, O.-B., & Storstein, A. (2017). Epidemiology of Parkinson's disease. Journal of Neural Transmission, 124(8), 901–905.
https://doi.org/10.1007/s00702-017-1686-y - Waller, S., Williams, L., Morales-Briceño, H., & Fung, V. (2021). The initial diagnosis and management of Parkinson's disease. Australian Journal for General Practitioners, 50, 793–800.
https://www1.racgp.org.au/ajgp/2021/november/diagnosis-and-management-of-parkinsons - Xu, Z., Anderson, K. N., Saffari, S. E., Lawson, R. A., Chaudhuri, K. R., Brooks, D., & Pavese, N. (2021). Progression of sleep disturbances in Parkinson's disease: a 5-year longitudinal study. J Neurol, 268(1), 312–320.
https://doi.org/10.1007/s00415-020-10140-x - Yi, Q., Yu-Peng, C., Jiang-Ting, L., Jing-Yi, L., Qi-Xiong, Q., Dan-Lei, W., Jing-Wei, Z., Zhi-Juan, M., Yong-Jie, X., Zhe, M., & Zheng, X. (2022). Worse Sleep Quality Aggravates the Motor and Non-Motor Symptoms in Parkinson's Disease. Front Aging Neurosci, 14, 887094.
https://doi.org/10.3389/fnagi.2022.887094